Stockholm: XINT

Market CapSEK204.7m

Last Close SEK2.34

Xintela is a specialist developer of stem-cell based therapies, based on its proprietary integrin marker technology platform XINMARK. Initial focus is on osteoarthritis and solid tumours (oncology business, Targinta to be spun-off in H221).

More Xintela content >

Investment summary

Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter in the regenerative stem cell and oncology areas. Initial targets are osteoarthritis (OA), glioblastoma (GBM) and triple negative breast cancer (TNBC), all areas with significant unmet need. 2021 could be a transformational year with an expected start for a Phase I/IIa trial for OA and the planned spinoff of the oncology arm. ARDS optionality in the COVID-19 world presents an outside opportunity too. Potential deals or partnerships in animal OA and oncology are near-term triggers.

Content on Xintela
Xintela – Advancing integrins as innovation engine
Healthcare | Initiation | 12 July 2021
Genetic engineering concept. DNA. Gene therapy. Medical technology.
View more
Register to receive research on Xintela as it is published
Share price graph
Price performance
Actual 4.0 (22.2) (54.8)
Relative* (3.3) (29.3) (69.2)
52-week high/low SEK5.6/SEK2.2
*% relative to local index
Key management
Evy Lundgren-Åkerlund CEO
Thomas Areschoug Chief business officer